[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yinghua Ji\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100603137","the-predictive-value-of-serum-histone-succinylation-in-malignant-solid-tumors-100603137",false,"NCT07132606","The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors","Serum Histone Succinylation: A Predictive Biomarker for Malignant Solid Tumors","Inclusion Criteria:\n\nCase Group:\n\n* Aged ≥18 years, regardless of sex；\n* Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy；\n\nControl Group:\n\n* Aged ≥18 years, regardless of sex；\n* Non-cancer participants enrolled through health screenings；\n\nExclusion Criteria:\n\n* Pregnant individuals；\n* Individuals with serious mental disorders or communication barriers；\n* Other conditions deemed by investigators to contraindicate study participation；",true,"ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","6 Months","OBSERVATIONAL","In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis.\n\nThis project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from \"gene-driven\" to \"epigenetic-metabolic-driven\" early detection.",[26],"Malignant Tumors","NOT_YET_RECRUITING","2025-08-17",{"date":30,"type":31},"2025-08-20","ACTUAL",{"date":30,"type":21},{"date":34,"type":21},"2026-08-01",{"name":36,"class":37},"Yinghua Ji","OTHER",""]